CombiCoR-Vax trial: study protocol for a phase II, single-arm, multicenter trial of sequential pembrolizumab plus dendritic cell vaccine followed by trifluridine/tipiracil and bevacizumab in refractory microsatellite-stable metastatic colorectal canc
This study, acronym CombiCoR-Vax, has been registered on clinicaltrials.gov registry with identifier NCT06522919, on July 9, 2024.
Authors
- Maria Laura Iaia
- Laura Matteucci (ORCID: https://orcid.org/0000-0001-9199-3746)
- Emanuela Scarpi (ORCID: https://orcid.org/0000-0001-7230-9267)
- Anna Miserocchi
- Jenny Bulgarelli (ORCID: https://orcid.org/0000-0002-6551-0189)
- Emiliano Tamburini (ORCID: https://orcid.org/0000-0003-4619-7091)
- Francesco De Rosa (ORCID: https://orcid.org/0000-0003-0511-1298)
- Alessandro Bittoni (ORCID: https://orcid.org/0000-0002-4056-0067)
- I. Toma
- Chiara Zani
- Marcella Tazzari (ORCID: https://orcid.org/0000-0002-8112-1773)
- Laura Ridolfi (ORCID: https://orcid.org/0000-0003-1870-3380)
- Francesco Giulio Sullo (ORCID: https://orcid.org/0000-0002-6478-0638)
- Massimiliano Petrini (ORCID: https://orcid.org/0000-0002-8942-0890)
- Sara Testoni (ORCID: https://orcid.org/0000-0001-6141-8783)
- Alessandro Passardi (ORCID: https://orcid.org/0000-0002-7099-240X)
- Maria Teresa Mita
- Massimo Viola
- Ottavia Tartagni
Institutions
- Cardinal Health (Australia) (AU)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Ospedale Civile di Giaveno (IT)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1186/s12885-025-15371-7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00